To determine the clinical significance of PAD2 in tamoxifen-resistant breast tumors, we first examined PAD2 mRNA level in clinical tumor tissue microarray during tamoxifen therapy using the publicly GEO dataset GDS806/11785 (https://www.ncbi.nlm.nih.gov/geoprofiles) [24]. Here, PADI2 is linked to breast neoplasm.